Key result
Percutaneous transeptal debulking with the AngioVac system was described as a procedural technique for an inoperable patient with mitral valve endocarditis.
Why the study?
Percutaneous transeptal debulking with AngioVac for mitral valve endocarditis in inoperable or high surgical risk patients has not been well defined.
Case Report (n=1)
Percutaneous transeptal debulking with the AngioVac system may offer a feasible procedural option for high-risk, inoperable patients with left-sided infective endocarditis.
May support feasibility of transeptal AngioVac for high-risk mitral endocarditis; leaves open need for prospective validation.
Vacuum assisted aspiration with the AngioVac system has been well described for; right sided endocarditis, venous thrombus, lead related infection/thrombus aspiration and right sided cardiac mass evacuation. Percutaneous transeptal debulking with AngioVac for mitral valve endocarditis (MVE) in the inoperable or high surgical risk patient has not been well defined. A significant proportion of high/prohibitive surgical risk patients with left sided infective endocarditis (IE) are not offered valve surgery as patients in the acute active phase of IE have a high surgical mortality. Nonetheless, sequala of acute IE ie stroke, sepsis or hemodynamic instability in itself is associated with high morbidity and mortality without surgical treatment. A case report of an inoperable patient with methicillin sensitive staphylococcus aureus MVE who was offered MV vegetation debulking with the AngioVac Gen3 C 180 MV system is described. Preprocedural planning with attention to; optimal transeptal height puncture, use of sentinel cerebral protection device to decrease risk of procedure related cerebral embolism and venous extracorporeal membrane cannula, rather than arterial cannula for reinfusion, is described to avoid large bore arterial access related vascular complications. Further studies in a randomized manner are warranted to test these procedural techniques and determine outcomes of percutaneous aspiration of left sided IE with the AngioVac system in this highrisk inoperable cohort of patients.
No takes yet. Share an insight, caveat, or question.
Memon et al. (2022) conducted a case report in Mitral valve endocarditis (n=1). Percutaneous transeptal debulking with AngioVac Gen3 C 180 MV system was evaluated. Percutaneous transeptal debulking with the AngioVac system was described as a procedural technique for an inoperable patient with mitral valve endocarditis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: